• Fri, January 8, 2021
Joseph Schwartz Maintained (SRPT) at Buy with Decreased Target to $125 on, Jan 8th, 2021
Joseph Schwartz of SVB Leerink, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $197 to $125 on, Jan 8th, 2021.
Joseph has made no other calls on SRPT in the last 4 months.
There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Joseph's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Joseph
- Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $212 on, Wednesday, October 28th, 2020
- Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $190 on, Tuesday, September 15th, 2020
